Related Experiment Video
Updated: Mar 24, 2026

05:56
Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
Published on: June 21, 2024
2.4K
A brief yoga intervention implemented during chemotherapy: A randomized controlled pilot study.
Complementary Therapies in Medicine
|March 16, 2016
Summary
This study found that a brief yoga intervention is feasible for patients with colorectal cancer undergoing chemotherapy. Yoga Skills Training (YST) showed high adherence and retention, supporting future research on its benefits.
Area of Science:
- Oncology
- Integrative Medicine
- Clinical Trials
Background:
- Fatigue and sleep disturbance significantly impact quality of life for cancer patients during chemotherapy.
- Yoga interventions show promise in mitigating treatment-related symptoms.
Purpose of the Study:
- To assess the feasibility of a randomized controlled trial for a brief yoga intervention in colorectal cancer patients receiving chemotherapy.
- To inform future research by collecting preliminary data on outcomes and challenges.
Main Methods:
- Adult patients with colorectal cancer were randomized to Yoga Skills Training (YST) or an attention control (AC).
- Interventions were delivered individually during chemotherapy infusions, with recommended home practice.
- Feasibility outcomes included accrual, retention, adherence, and data collection.
Main Results:
- 15 out of 52 identified patients enrolled, with 75% retention in the YST group and 71% in the AC group.
- Participants demonstrated high adherence (97%) to in-person intervention sessions and completed all questionnaires.
- Preliminary data on fatigue, sleep, quality of life, and biomarkers were collected.
Conclusions:
- A larger randomized controlled trial of Yoga Skills Training for colorectal cancer patients undergoing chemotherapy is feasible.
- The study provides valuable insights into recruitment, retention, and data collection for future research.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
927
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
927
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Cancer Therapies
10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Cancer Therapies
3.0K
3.0K
Treatment Resistent Cancers
1.5K
1.5K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
786
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
786